# Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine

> **NCT00742885** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 100 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted

## Key facts

- **NCT ID:** NCT00742885
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09-01
- **Primary completion:** 2009-03-07
- **Final completion:** 2009-03-07
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2018-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00742885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00742885, "Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00742885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*